about
Acute optic neuritis: Unmet clinical needs and model for new therapiesThe King-Devick test for sideline concussion screening in collegiate footballCross-sectional evaluation of clinical neuro-ophthalmic abnormalities in an amyotrophic lateral sclerosis population.Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire.Laser pointer visual field screening.Re-evaluating the treatment of acute optic neuritis.Treatment of acute demyelinating optic neuritis.Objectifying eye movements during rapid number naming: Methodology for assessment of normative data for the King-Devick test.Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis.Diagnostic tests for concussion: is vision part of the puzzle?Education research: a new system for reducing patient nonattendance in residents' clinic.Post-traumatic headache: the use of the sport concussion assessment tool (SCAT-3) as a predictor of post-concussion recovery.Retinal architecture and mfERG: Optic nerve head component response characteristics in MSLongitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis.Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection.Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of observational studies.Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.Sports-related concussion testing.Pearls and oy-sters: central fourth nerve palsies.Health-related quality of life in multiple sclerosis: effects of natalizumab.Transcervical thymectomy for myasthenia gravis achieves results comparable to thymectomy by sternotomy.Trigeminal neuralgia: historical notes and current concepts.Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.Diagnosis and management of orbital pseudotumor.The role of unilateral temporal artery biopsy.Vision in a phase 3 trial of natalizumab for multiple sclerosis: relation to disability and quality of lifeMultiple sclerosis and the visual system.Residency training: the King-Devick test and sleep deprivation: study in pre- and post-call neurology residents.Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates.IgG4-related inflammatory pseudotumor of the central nervous system responsive to mycophenolate mofetil.The neuro-ophthalmology of multiple sclerosis.US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.Retinal ganglion cell layer volumetric assessment by spectral-domain optical coherence tomography in multiple sclerosis: application of a high-precision manual estimation technique.Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.Advances in neurological education: a time to share.Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET.Multiple sclerosis and the ophthalmologist.Ganglion cell loss in relation to visual disability in multiple sclerosis.One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis.
P50
Q26799784-CF5C4ADC-099A-4ED5-9047-078FC7900782Q28392080-CB908629-D0D2-4EC8-AB31-028332CD4474Q30524895-60C1182F-099C-428A-B35C-7A6CC85F315AQ30691130-643BB20B-A169-41BC-9F5D-3CF9D3CD46A0Q30826691-ED47B228-EDDD-437A-88B4-89D883BC3662Q30865447-27CA0B9B-BBE4-4263-B4D9-37CFBFA19328Q30974206-9FEA2DE0-6234-43D8-97D0-3F0AE9DAACABQ31053021-8A97DB23-E530-40FC-8556-3D98818ADE7DQ31162456-C164E039-6056-4B0A-AFA4-6A8606E0F195Q33351599-6DE413BA-2A94-46C5-BE99-2E6BE99665A4Q33360042-E7B95793-4748-4886-B058-689F4482872EQ33730334-9A041FFB-F74E-428C-896E-0E1FE128A185Q33740426-BD8B5437-221A-4956-90D4-54CF26F775B5Q33927190-C0B5715D-64AC-4A2E-99D8-0548FFEF53AEQ33983613-DC070E55-BEF2-4677-8F85-757C8F2CF2D5Q34076168-273E2A6E-9B91-491F-B8DD-7932063F37F4Q34080426-FD1CB684-1E53-4695-8C7D-B4F1E595742AQ34104397-3D1B5058-205A-4542-9403-0C44D9D189D6Q34335188-1A5E6DFF-DB49-44D7-AC9B-48B0D3808688Q34501372-E3ECCE12-9DEF-4AEB-A755-ED6A560C184FQ34662511-A9FA8744-D94A-4F1C-BA24-244C16E9580FQ34782301-455EEDB0-67E1-4BCF-9128-4942C99663F0Q34960656-DE06EA24-FB7F-4415-9FA5-4CAD80328027Q34975819-413B51B7-1132-40C7-92CD-695E9F35FDA5Q35004170-C2EDC714-A3E8-4F3F-A2F1-80A7C1BF0DECQ35080463-6C724674-BE27-425A-A891-3379E06154D5Q35111163-AC52F999-2186-43D1-B50A-ADD05181F52BQ35874527-26DFB35F-2F07-40B4-A508-BF8E274D44C9Q35909834-2DDDAC1F-C8F5-4FC7-997A-F21B69387029Q35924577-EC4D6B78-EDFB-4817-989C-A4A2B6F9DD3CQ36004130-F5D2F0D5-CA9E-45BF-A256-70EC2D01CBBCQ36017333-FB6EF99C-B6E7-4005-A653-C9D2FE3C6756Q36058902-1056E2A6-538C-4F8D-AAD7-F207C73E9760Q36143046-D70CA635-D2B2-4EBA-B503-798C51EC32ADQ36190102-C77EA374-A01E-4813-9BCE-B439E3017AAAQ36432494-05E5C73E-63B4-4BF9-AEDB-122D673EFDEEQ36608504-A15CE0D5-7253-45A9-B060-F642729617FAQ36774327-BEA82867-AEB6-47AD-B311-72FF5B0D2624Q36781704-C8E44817-6D4F-4576-A49E-A7383523E54BQ36799833-AB6F4F22-E8ED-40E6-8444-2024C89F4514
P50
description
onderzoeker
@nl
name
Steven Galetta
@ast
Steven Galetta
@en
Steven Galetta
@es
Steven Galetta
@nl
type
label
Steven Galetta
@ast
Steven Galetta
@en
Steven Galetta
@es
Steven Galetta
@nl
altLabel
Galetta S
@en
Galetta S. L.
@en
Galetta S.
@en
Galetta SL
@en
Galetta
@en
S Galetta
@en
S L Galetta
@en
S. Galetta
@en
S. L. Galetta
@en
Steven L Galetta
@en
prefLabel
Steven Galetta
@ast
Steven Galetta
@en
Steven Galetta
@es
Steven Galetta
@nl
P214
P106
P214
P31
P4012
P7859
lccn-n92905985